Leica Biosystems has announced the acquisition of StatLab Medical Products, a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity.
Gustavo Perez-Fernandez, Group Executive Danaher‘s Diagnostics Business, and President, Leica Biosystems said: “We are pleased to officially welcome StatLab to Leica Biosystems. uniting StatLab’s trusted portfolio and deep customer relationships with Leica Biosystems’ global leadership in digital and computational pathology and AI-enabled diagnostics.
“Together, we are even better positioned to help laboratories achieve the consistency, standardisation, and quality needed to advance precision oncology at scale. When clinicians have access to timely, high-quality needed to advance precision oncology at scale. When clinicians have access to timely, high-quality diagnostic information, they are better equipped to understand each patient’s cancer and determine the most appropriate care approach. Every step we take to accelerate critical cancer diagnostics helps patients get on the path to treatment faster.”
Leica Biosystems says that by bringing together complementary capabilities across the pathology workflow, the company is bolstering its comprehensive end-to-end portfolio, from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis.
The company says the expanded offering is designed to help pathology laboratories optimise critical histology workflows, reduce variation and move from sample to answer with greater speed, consistency and confidence.
Leica also claims that the expanded offering will help clinicians deliver more timely answers for the patients who depend on them, as well as supporting the continued advancement of precision cancer therapies through its work with biopharma partners.
